OncoMed Pharmaceuticals Culture Company

Dr. Austin Gurney, Ph.D. has been Chief Scientific Officer and Senior Vice President at OncoMed Pharmaceuticals, Inc. since August 22, 2017. Dr. Gurney served as Senior Vice President of Molecular and Cellular Biology at OncoMed Pharmaceuticals, Inc. since December 2009 until August 22, 2017 and served as its Co-Chief Scientific Officer since January 2016 until August 22, 2017. Dr. Gurney served as a Vice President of Molecular & Cellular Biology at OncoMed Pharmaceuticals, Inc. from 2004 to December 2009 and served as its Clinical and Scientific Advisor. Dr. Gurney served as a Vice President of Molecular Biology of OncoMed Pharmaceuticals, Inc. Dr. Gurney was a Leader of the SPDI team of Genentech, where he was responsible for organizing the identification and cloning of all cell surface molecules of interest. He joined Genentech as a Scientist and during his 12 year tenure he was promoted to Senior Scientist and to Acting Director of the Department of Molecular Biology. He was responsible for numerous patents on the secretion of proteins, cell surface receptor identification and function and has authored of 60 papers in the field. Dr. Gurney received his PhD from Case Western Reserve in Biochemistry and Molecular Biology in 1992. He pursued Post Doctoral studies with Dr. Bryan Williams at the Cleveland Clinic and at Genentech with Dr. David Goeddel.

Mr. Sunil Patel has been Chief Financial Officer and Executive Vice President at OncoMed Pharmaceuticals, Inc. since March 31, 2014 and since October 03, 2017 respectively and served as its Executive Vice President of Corporate Development & Finance from September 19, 2017 to October 03, 2017. Mr. Patel served as Senior Vice President of Corporate Development & Finance at OncoMed Pharmaceuticals, Inc. since March 31, 2014 until September 19, 2017 and also served as its Chief Business Officer and Senior Vice President since December 2012 until March 31, 2014 and Senior Vice President of Corporate Development since July 2009 until December 2012. He joined OncoMed from BiPar Sciences, Inc. He was the Vice President of Corporate Development and Marketing at BiPar Sciences, Inc., since September 2008 and was responsible for all its corporate development and marketing activities. Mr. Patel worked at Allos Therapeutics, Inc., where he served as Vice President of Corporate Development and led all its partnering, in-licensing and merger and acquisition activities. He served as Vice President of Corporate Development and Strategy of Connetics Corporation since May 2006. Mr. Patel has over 17 years of pharmaceutical and biotechnology experience. He held positions at Abgenix Inc., ProCyte, Gilead Sciences Inc., McKinsey & Company and ZymoGenetics Inc. He served as Senior Director of Strategic Marketing at Abgenix Inc. , where he was responsible for corporate development, M&A and marketing activities. He has been an Independent Director of Ligand Pharmaceuticals Incorporated since October 2010 and Cubist Pharmaceuticals Inc. since January 2015. Mr. Patel holds a B.S. in Chemistry from the University of California, Berkeley and an M.S. in Molecular Bioengineering/Biotechnology from the University of Washington.

Dr. Alicia J. Hager, J.D., Ph.D. has been General Counsel of OncoMed Pharmaceuticals, Inc. since December 2012 and has been its Senior Vice President since February 1, 2017. Dr. Hager served as a Vice President of OncoMed Pharmaceuticals, Inc. since December 2012 until February 1, 2017. Dr. Hager served as Vice President of Legal Affairs and Chief Patent Counsel at OncoMed Pharmaceuticals, Inc. since July 2010 and November 2008 respectively. From June 2008 to October 2008, she served as a Senior Patent Counsel. Dr. Hager is an attorney with over 12 years of experience in providing strategic IP counseling to biotech and pharmaceutical companies and preparing and prosecuting patent applications in the life science fields. She joined OncoMed in June 2008 from the Palo Alto office of Morrison & Foerster LLP. Prior to Morrison & Foerster, Dr. Hager was a Registered Patent Agent and Law Clerk at Heller Ehrman White & McAuliffe LLP. At Harvard, her thesis research with Nobel Prize winner Dr. Jack Szostak focused on the in vitro selection of novel ribozymes. She received her undergraduate degree in chemistry from Occidental College. Dr. Hager received her JD from Stanford Law School, with distinction and her PhD in Chemistry from Harvard University.

Dr. John A. Lewicki, Ph.D. has been an Executive Vice President of Research and Development at OncoMed Pharmaceuticals, Inc. since January 2016. Dr. Lewicki served as Chief Scientific Officer and Executive Vice President of OncoMed Pharmaceuticals, Inc. from December 2009 to January 2016. Dr. Lewicki served as a Senior Vice President of Research and Development at OncoMed Pharmaceuticals, Inc. since 2004 and served as its Clinical and Scientific Advisor. He joined OncoMed after serving 16 years with Scios Inc., where he managed OncoMed Pharmaceuticals Inc.'s research organization across diverse therapeutic areas. Among his many achievements with OncoMed was the co-discovery of Natrecor an FDA approved drug for congestive heart failure. He joined Scios in 1983 as a Scientist and served as its Senior Scientist since 1984, Vice President of Research since August 1986, Vice President and Deputy Director of Research since March 1987 and Vice President and Director of Research since February 1988. He was a Research Pharmacologist at Stanford University, Division of Clinical Pharmacology from 1981 to 1983. He is the Author of more than 70 research papers and book chapters and is an Inventor on 22 issued US patents. Dr. Lewicki received his Ph.D. in Physiology/Pharmacology from the University of California, San Diego in 1979. From 1979 to 1981, he conducted postdoctoral training at the University of Virginia, Department of Internal Medicine.

Alicia Hager serves as the Senior Vice President and General Counsel of OncoMed Pharmaceuticals. Alicia started at OncoMed Pharmaceuticals in January of 2017. Alicia currently resides in San Francisco Bay Area.

Jill Henrich serves as the Senior Vice President, Regulatory Affairs and Quality Assurance of OncoMed Pharmaceuticals. Jill started at OncoMed Pharmaceuticals in June of 2018. Jill currently resides in San Francisco Bay Area.

John Lewicki serves as the Executive VP and Chief Scientific Officer of OncoMed Pharmaceuticals. John started at OncoMed Pharmaceuticals in July of 2004. John currently resides in San Francisco Bay Area.